

Germany

Tuberculosis profile

Population 2015

81 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.32 (0.31–0.32)	0.39 (0.39–0.4)
Mortality (HIV+TB only)	0.026 (<0.01–0.13)	0.03 (0–0.16)
Incidence (includes HIV+TB)	6.5 (5.6–7.5)	8.1 (6.9–9.3)
Incidence (HIV+TB only)	0.2 (0.15–0.25)	0.24 (0.19–0.3)
Incidence (MDR/RR-TB)**	0.23 (0.11–0.34)	0.29 (0.14–0.42)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.18 (0.085–0.27)	1.8 (1.1–2.5)	2 (1.2–2.8)
Males	0.22 (0.15–0.3)	4.3 (3.4–5.2)	4.5 (3.5–5.5)
Total	0.4 (0.29–0.51)	6.1 (5.6–6.7)	6.5 (5.6–7.5)

TB case notifications, 2015

Total cases notified	5 865
Total new and relapse	5 671
- % tested with rapid diagnostics at time of diagnosis	54%
- % with known HIV status	
- % pulmonary	77%
- % bacteriologically confirmed among pulmonary	81%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.05 (0.04–0.07)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive		
- on antiretroviral therapy		

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			170 (89–240)
Estimated % of TB cases with MDR/RR-TB	2.2% (0.82–4.8)	23% (16–30)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: , XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: , XDR-TB:	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	63%	4 283
Previously treated cases, excluding relapse, registered in 2014	64%	143
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013	39%	105
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016

National TB budget (US\$ millions)	
------------------------------------	--


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse

— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB